Safety and Efficacy of LCI699 in Cushing's Disease Patients
A phase 2 trial of Osilodrostat in Pituitary tumours, run by Novartis Pharmaceuticals, completed.
Overview
Safety and Efficacy of LCI699 in Cushing's Disease Patients is a phase 2 interventional study registered as NCT01331239 by Novartis Pharmaceuticals, with 31 participants recorded, started 2011-03-23 and reaching its primary completion in 2019-10-22. Interventions recorded: LCI699. Conditions recorded: Cushings Disease, Cushing Disease.
Linked to the drug Osilodrostat because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialEfficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
Shares Osilodrostat, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TreatmentMetyrapone
Shares Osilodrostat, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma.
- TrialMulticenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialStudy of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialStrict IGF-1 Control in Acromegaly
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialCabergoline in Nonfunctioning Pituitary Adenomas
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.